logo
Bernard Arnault hopes for luxury turnaround

Bernard Arnault hopes for luxury turnaround

Daily Mail​a day ago
Bernard Arnault is hoping for a turnaround when his luxury empire updates investors.
The wealth of the Frenchman (pictured with Ivanka Trump), whose empire includes Louis Vuitton and Dior, has fallen by more than £15billion this year. But he is still one of the world's richest men - worth £116billion despite a 26 per cent slide in LVMH shares.
On Thursday LVMH, whose sales fell earlier this year, announces its second-quarter figures.
Arnault, who attended Donald Trump's inauguration, hoped rich Americans splashing out would offset a slowdown in China. But demand has been hit by trade war tension between the US and China.
Its alcohol brands, such as Moet champagne, have also been hit hard by tariffs and waning demand.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca unveils plans for £37bn investment in US amid tariff threats
AstraZeneca unveils plans for £37bn investment in US amid tariff threats

The Independent

time21 minutes ago

  • The Independent

AstraZeneca unveils plans for £37bn investment in US amid tariff threats

Drug maker AstraZeneca has announced plans to invest 50 billion dollars (£37 billion) in the US over the next five years amid the looming threat of President Donald Trump's trade tariffs. The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'

Bold new (Amp)era: inside the new generation of range-extender engines
Bold new (Amp)era: inside the new generation of range-extender engines

Auto Car

time21 minutes ago

  • Auto Car

Bold new (Amp)era: inside the new generation of range-extender engines

Scharrer sees huge market potential in areas where charging infrastructure remains a barrier to EV sales success. 'I hear comments that this is a very short-term technology and that regulations aren't following,' he laments. 'But if you have a car capable of going 155 miles fully electric, then it has a range-extender for the countryside, why should you be banned from driving it in the city? 'We involve ourselves as much as we can in regulatory discussions. In China, to keep the status of a 'new-energy vehicle' [EVs and plug-in hybrids], you must not connect the internal combustion engine to the wheels. The EU has not finally decided what to do with range-extenders, but I think they realise that this is an interesting opportunity to offer a product which is less dependent on rare materials and cell chemistry because you need a significantly smaller battery. 'They want to understand what the pros and cons are. The whole mobility community is ready for these discussions, because we need them. The past regulation of BEVs has shown that we cannot push things into the market against the customers' will. The easier a solution is, the higher its chance of surviving a long time. And this is quite an easy solution. I personally expect that we will see it beyond the next five to 10 years. I think there will be plenty of applications which really excite people.'

AstraZeneca to invest $50bn in US amid fears it could quit Britain
AstraZeneca to invest $50bn in US amid fears it could quit Britain

Telegraph

time22 minutes ago

  • Telegraph

AstraZeneca to invest $50bn in US amid fears it could quit Britain

AstraZeneca has unveiled plans to invest $50bn (£37bn) in the US by the end of the decade amid fears it could ditch the London stock market. The British drugmaker said the huge investment in both medicines manufacturing and research and development will help fuel its aim of reaching $80bn in revenues by 2030, half of which will be generated in the US. The announcement, which comes on top of a $3.5bn spending push announced late last year, will fuel speculation that the pharmaceutical giant is weighing up a move to the US. Reports earlier this month said Sir Pascal Soriot, AstraZeneca's chief executive, had discussed moving the company's listing to the US and shifting its domicile away from the UK. AstraZeneca has declined to comment on the reports. The spending spree also comes in the wake of Donald Trump's threats to impose tariffs of as much as 200pc on medicines imported to the US. The US president has encouraged pharmaceutical companies to move their factories to America. Earlier this month he said he would give businesses 'a year or so to build' before ramping up levies. AstraZeneca said the cornerstone of its US investment plan would be a new drug manufacturing facility focused on chronic diseases. The factory, to be built in Virginia, will mark the company's largest single manufacturing investment to date. The investment plan also includes the construction or expansion of manufacturing and research facilities in Maryland, Massachusetts, California, Indiana and Texas. Howard Lutnick, US Secretary of Commerce, said: 'For decades, Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.' While AstraZeneca is listed in London and headquartered in Cambridge, the US is its largest market, accounting for roughly 42pc of revenues. The company already operates 19 sites and employs more than 18,000 people in the US. Sir Pascal has grown increasingly frustrated with the UK in recent years, criticising its tax rates, high NHS rebates and refusal to buy new medicines. In 2023, AstraZeneca said it had decided not to build a new $400m drug factory in Britain because of its 'discouraging' tax regime, while last year it scrapped plans for a separate £450m vaccine facility in Liverpool after the Government cut the financial support available. AstraZeneca is the largest listed business in the UK and any decision to move the company would come as an enormous blow to the London Stock Exchange, which is already reeling from a wave of departures and dearth of new listings. It would also be an embarrassing setback for the Government, which last week published its long-awaited life sciences sector plan. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80bn in revenue by 2030.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store